2024 Updates in Thrombosis & Hemostasis — On Demand

Wednesday, December 4, 2024, 9:00 AM - Monday, June 30, 2025, 11:00 PM

This on-demand symposium, originally recorded live on October 27, 2024, delivers the latest advancements in benign hematology, with a special emphasis on venous thromboembolism (VTE) and anticoagulation. The 2024 program centers on three key topics:

— Current challenges in Venous Thromboembolism 
— Novel anticoagulants
— Thrombotic complications of clonal disorders

This comprehensive program covers key topics such thrombophilia testing, the role of interventional radiology in VTE management, and challenging scenarios such as chronic thromboembolic pulmonary hypertension (CTEPH), refractory thrombosis, and splanchnic thrombosis. Faculty also review the reversal of direct oral anticoagulants, novel factor XI inhibitors, and unique challenges in the management of thrombosis and clonal disorders (e.g., PNH and myeloproliferative neoplasm).  Each presentation also includes a recorded Q&A session. For more information about what's available in this on-demand program, including a detailed list of presentations, view the brochure from the live symposium.

The target audience includes general medicine practitioners, hematologists/oncologists, intensivists, emergency medicine practitioners, primary care physicians, residents, fellows, advanced practice providers, and other healthcare professionals involved in the management and treatment of thrombotic and bleeding disorders.

1. Provide guidance and updates on management of challenging thrombotic conditions including indications for thrombophilia testing, role of interventional radiology, management of refractory thrombosis, PNH, and anticoagulation in brain tumors.
2. Summarize recent data on management of anticoagulant related hemorrhage and discuss emerging FXI inhibitors and their potential for improved safety profiles.
3. Recognize the challenges in managing thrombo-hemorrhagic risks in patients with myeloproliferative neoplasms.

Access to the on-demand content requires registration. Once registered, all materials, including relevant financial disclosures and instructions for claiming credit, are located under the 'Course Content' tab. This on-demand program is available for purchase until June 30, 2025. For those that purchase this on demand, access to the content, as well as the opportunity to claim credit, is available through September 30, 2025.

On Demand Access Fees
— Physicians (MDs, PhDs, and DOs): $300
— Advanced Practice Providers: $250
— Nursing and Other Healthcare Professionals: $200
— Residents, Fellows, and Students: $100 
— MSK Employees: Complimentary

Discounted registration is available for specific groups. If eligible, you will receive further instructions and a promotion code to use during registration. View our Policy on Registration Discounts for more information and to submit a request. Please note that after your payment has been processed, no further promotional discounts or adjustments will be made to your registration.

This Memorial Sloan Kettering Continuing Medical Education on-demand program is non-refundable.

Memorial Sloan Kettering Cancer Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

AMA Credit Designation Statement

Memorial Sloan Kettering Cancer Center designates this enduring material for a maximum of 4.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC/CC Recognition Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to:

— 4.50 Medical Knowledge MOC Points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification Assessment Recognition program; and
— 4.50 Lifelong Learning (CME) credit towards the American Board of Pathology’s (ABPath) Continuing Certification program.

It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM or ABPath MOC credit.

MOC/CC points will be reported to your board within 45 days upon completion of the course.

Recorded/Review Date: October 27, 2024 | Original Release Date: December 4, 2024 | Termination Date: September 30, 2025

MSK Symposium Director

Jeffrey Zwicker, MD
Chief, Hematology Service



MSK Symposium Co-Director 

Rekha Parameswaran, MD
Attending, Hematology Service 



MSK Symposium Planning Committee

Kuo-Kai Chin, MD
Hematology-Oncology Chief Fellow

Avi Leader, MD
Assistant Attending, Hematology Service 

Jodi V. Mones, MD
Associate Program Director, Medical Oncology/Hematology Fellowship, Hematology Track;
Associate Attending, Hematology Service 

Michael Philbin, PhD
Patient Planner

Cara Scotti, PA
Advanced Practice Provider

Cy R. Wilkins, MD
Assistant Attending, Hematology Service 

 

Symposium Invited Faculty 

Kenneth A. Bauer, MD
Professor of Medicine
Harvard Medical School
Division of Hemostasis and Thrombosis
Beth Israel Deaconess Medical Center

Evelyn M. Horn, MD
Director, Perkin Heart Failure Center
Advanced Heart Failure & Pulmonary Vascular Disease Programs
Professor of Clinical Medicine, Weill Cornell
Adjunct Professor, Columbia University
Weill Cornell Medicine

Peter L. Gross, MD
Associate Professor
University of Toronto

Rushad Patell, MD
Assistant Professor of Medicine
Beth Israel Deaconess Medical Center

Deborah Siegal, MD, MSc, FRCPC 
Associate Professor, Department of Medicine and School of Epidemiology and Public Health, University of Ottawa
Scientist, Ottawa Hospital Research Institute

 

MSK Symposium Faculty 

Yolanda Bryce, MD
Assistant Attending, Interventional Radiology Service

Maly Fenelus, MD, MPH
Assistant Director, Clinical Hematology Laboratories;
Director, MSK Nassau Clinical Laboratory;
Assistant Attending
Department of Pathology and Laboratory Medicine

Ioanna Kosmidou, MD
Associate Attending, Cardiology Service

Raajit K. Rampal, MD, PhD
Director, Center for Hematologic Malignancies;
Director, Myeloproliferative Neoplasms Program;
Associate Attending, Leukemia Service

Jessica A. Wilcox, MD
Assistant Attending, Brain Tumor Service

Mitigation of Relevant Financial Relationships

Memorial Sloan Kettering Cancer Center adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all financial relationships with ineligible companies (commercial interests). All relevant financial relationships have been mitigated prior to the commencement of the activity.